-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-8009 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-8009 in Peritoneal Cancer Drug Details: BT-8009 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Metenkefalin in Kaposi Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Metenkefalin in Kaposi Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Metenkefalin in Kaposi Sarcoma Drug Details: IRT-101 (methionine-enkephalin) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Entolimod in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Entolimod in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Entolimod in Non-Small Cell Lung Cancer Drug Details: Entolimod (CBLB-502)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naltrexone Hydrochloride in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naltrexone Hydrochloride in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone Hydrochloride in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Metenkefalin in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Metenkefalin in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Metenkefalin in Human Immunodeficiency Virus (HIV) Infections (AIDS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Metenkefalin in Kaposi Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Metenkefalin in Kaposi Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Metenkefalin in Kaposi Sarcoma Drug Details: IRT-101 (methionine-enkephalin) is under development for...
-
Product Insights
NewAddictive Disorders – Drugs In Development, 2024
Empower your strategies with our Addictive Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Addictive disorders, such as substance abuse and dependence, are common disorders that involve the overuse of alcohol and/or drugs. Addiction develops over time and is a chronic and relapsing illness. Addictive disorders are caused by multiple factors, including genetic vulnerability, environmental stressors, social pressures, individual personality characteristics and psychiatric problems. The Addictive Disorders drugs in development market research report provide comprehensive information...
-
Product Insights
NewFibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2024
Empower your strategies with our Fibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis, or lupus. Treatment includes pain relievers, antidepressants, and anti-seizure drugs. The Fibromyalgia (Fibromyalgia Syndrome) drugs in development market research report provide comprehensive information...
-
Product Insights
NewKaposi Sarcoma – Drugs In Development, 2024
Empower your strategies with our Kaposi Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin; in the lining of the mouth, nose, and throat; or in other organs. Symptoms include patches that are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea. The...
-
Product Insights
NewPoliomyelitis – Drugs In Development, 2024
Empower your strategies with our Poliomyelitis – Drugs In Development, 2024 report and make more profitable business decisions. Polio is a highly infectious disease caused by a virus. It invades the nervous system and can cause total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck, and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio. The Poliomyelitis drugs in development market research report provide comprehensive information...